BioMarin Pharmaceutical (BMRN) vs Summit Therapeutics (SMMT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
BioMarin Pharmaceutical (BMRN) has outperformed Summit Therapeutics (SMMT) over the past year, gaining 0.4% versus a loss of 26.4%. Over five years, SMMT leads with a +233.4% price change compared with -27.7% for BMRN. Summit Therapeutics is the larger company by market cap ($13.70 billion vs $10.63 billion), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BMRN | SMMT |
|---|---|---|
| Share price | $54.89 | $17.17 |
| Market cap | $10.63B | $13.70B |
| 1-day change | -0.56% | -4.35% |
| YTD return | -7.64% | -1.83% |
| 1-year return | +0.37% | -26.44% |
| 5-year return | -27.67% | +233.40% |
| P/E ratio (TTM) | 148.35 | — |
| Forward P/E | 8.28 | — |
| EPS (TTM) | $0.37 | $-1.11 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $3.22B | — |
| Revenue growth (YoY) | +12.87% | — |
| Net income (latest FY) | $348.90M | $-1.08B |
| Gross margin | 77.73% | — |
| Operating margin | 12.71% | — |
| Net margin | 10.83% | — |
| 52-week high | $70.98 | $29.23 |
| 52-week low | $49.26 | $12.07 |
| Distance from 52-week high | -22.67% | -41.26% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +66.92% | +73.27% |
| Average volume | 2.04M | 5.82M |
| Shares outstanding | 193.57M | 797.75M |
| Employees | 3,221 | 265 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BMRN has outperformed SMMT by 26.8 percentage points over the past year.
About BioMarin Pharmaceutical
BMRN stock →BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations.
Health Care · Biotechnology: Pharmaceutical Preparations · 3,221 employees
About Summit Therapeutics
SMMT stock →Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC).
Health Care · Biotechnology: Pharmaceutical Preparations · 265 employees
BMRN vs SMMT FAQ
Which is bigger, BioMarin Pharmaceutical or Summit Therapeutics?
Summit Therapeutics (SMMT) is larger, with a market capitalization of $13.70B compared with $10.63B for BioMarin Pharmaceutical (BMRN).
Which stock has performed better over the past year, BMRN or SMMT?
BMRN returned +0.37% over the past 12 months, compared with -26.44% for SMMT (price return, excluding dividends). Past performance does not predict future results.
Are BioMarin Pharmaceutical and Summit Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.